NADH function is one of the most important biochemical processes in living cells. This coenzyme carries electrons during cellular energy production. It transfers energy from nutrients to create ATP—the cell's universal energy currency.
NAD and NADH's relationship drives many metabolic pathways in the body. NADH plays a key role in cellular respiration by moving electrons from food molecules to the electron transport chain. This process leads to ATP synthesis. NADH's role in glycolysis captures energy when glucose breaks down. NADH dehydrogenase helps transfer electrons at Complex I of the respiratory chain. This remarkable molecule connects various energy-producing pathways and keeps cells' redox balance in check.
This piece examines how NADH works in different parts of cells, its movement mechanisms, and its behavior under various conditions. Scientists have found promising therapeutic uses for NADH. Learning about these processes helps us understand basic cell operations and energy metabolism disorders better.
NADH Main Function in Cellular Respiration
NADH is the life-blood of cellular energy production and works as the main electron carrier that powers ATP synthesis. The NAD+/NADH redox couple regulates energy metabolism and coordinates both glycolysis and mitochondrial oxidative phosphorylation [1]. This molecule takes part in many reduction-oxidation (redox) reactions that help cells get energy from nutrients.
Electron Carrier in Redox Reactions
NADH's main job is to move electrons between metabolic reactions. This dinucleotide comes in two forms: NAD+ (oxidized) and NADH (reduced). NAD+ accepts electrons and hydrogen from energy-rich molecules and turns into NADH through this reaction:
RH₂ + NAD⁺ → R + H⁺ + NADH [2]
RH₂ represents any substrate getting oxidized (like glucose or other metabolites). NAD+ accepts two electrons and one hydrogen atom to become NADH. NADH then gives these electrons to the electron transport chain (ETC) and changes back to NAD+ through this reaction:
NADH → H⁺ + NAD⁺ + 2e⁻ [2]
Electrons from NADH enter the ETC at Complex I, which has nearly 40 polypeptide chains [3]. This transfer starts an energy-producing process that releases a lot of energy (ΔG°´ = -16.6 kcal/mol) [3]. The released energy pushes protons across the inner mitochondrial membrane and creates the proton gradient needed for ATP synthesis.
NADH oxidation at Complex I adds a lot to cellular energy production. Each NADH molecule that gets oxidized leads to the pumping of 10 protons through the ETC (4 from Complex I, 4 from Complex III, and 2 from Complex IV) [2]. ATP synthase needs about 4 protons to make one ATP molecule, so each NADH can make about 2.5 ATP molecules [2].
Link Between Glycolysis and Oxidative Phosphorylation
NADH connects different stages of cellular respiration. The process starts with glycolysis, where glucose breakdown makes two NADH molecules in the cytoplasm. This happens during glycolysis's sixth step, where glyceraldehyde phosphate dehydrogenase (GAPDH) changes glyceraldehyde 3-phosphate (G3P) to 1,3-bisphosphoglycerate and turns NAD+ into NADH [1].
The inner mitochondrial membrane blocks NADH from passing through [1]. Cells use special shuttle systems to solve this:
-
The malate-aspartate shuttle
-
The glycerol-3-phosphate shuttle
These shuttles move electrons from cytosolic NADH into mitochondria [1]. This process makes NAD+ in the cytosol for glycolysis while building up NADH in mitochondria for the ETC.
Inside mitochondria, NADH from both glycolysis and the tricarboxylic acid (TCA) cycle gives electrons to the ETC. The TCA cycle makes eight NADH molecules for each glucose molecule in aerobic conditions [1]. NADH forms at several points:
-
Pyruvate dehydrogenase (PDH) turns pyruvate into acetyl-CoA
-
Isocitrate dehydrogenase 3 (IDH3) oxidizes isocitrate
-
α-ketoglutarate dehydrogenase (KGDH) converts α-ketoglutarate
-
Malate dehydrogenase (MDH2) oxidizes malate [1]
Glycolysis and the TCA cycle together make ten NADH molecules from one glucose molecule [3]. These NADH molecules feed electrons into the ETC, where Complex I (NADH dehydrogenase) turns NADH back into NAD+.
This coordination between pathways shows NADH's central role in cellular bioenergetics. The constant cycling between NAD+ and NADH keeps redox balance in cellular compartments and allows steady energy production. On top of that, this balance helps regulate metabolism since too much NADH can stop important pathways like glucose, glutamine, and fat oxidation [4].
NADH does more than just carry electrons - it actively controls metabolic flow by affecting various enzyme reactions based on its concentration. This dual role makes NADH a key regulator of cellular energy metabolism that links carbohydrate breakdown to oxygen-dependent ATP production.
NADH Function in Glycolysis and the TCA Cycle
The cellular pathways of glycolysis and the tricarboxylic acid (TCA) cycle are metabolic hubs where NADH production happens through oxidation-reduction reactions. These pathways contain specialized enzymes that catalyze NAD+-dependent reactions and get NADH that powers ATP synthesis.
GAPDH and Pyruvate Dehydrogenase Roles
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) works as a highly conserved enzyme in the glycolytic pathway and catalyzes a vital redox reaction. This enzyme changes glyceraldehyde-3-phosphate into glycerate-1,3-bisphosphate and produces NADH in the cytoplasm. The reaction can't proceed without enough NAD+, which stops the entire glycolytic cascade. Aerobic cells must recycle the NADH back to NAD+ through oxidative phosphorylation, while anaerobic cells do this through fermentation.
GAPDH's NADH production helps maintain cellular redox balance. Research shows that GAPDH overexpression with three other genes increased intracellular NADH pools by 1.2 times in the bacteria Shewanella oneidensis [5]. GAPDH activity also helps produce NADPH in some organisms through the pyruvate-oxaloacetate-malate cycle, showing its adaptable role in cellular metabolism.
After glycolysis finishes, pyruvate molecules go through decarboxylation by the pyruvate dehydrogenase complex (PDC) to create acetyl-CoA. This reaction links glycolysis to the TCA cycle and creates more NADH. The PDC changes pyruvate to acetyl-CoA when it enters mitochondria, which reduces NAD+ to NADH [5]. One NADH molecule is produced for each pyruvate molecule changed to acetyl-CoA.
PDC needs several cofactors to work properly: thiamine pyrophosphate, lipoic acid, coenzyme A, and NAD+. The complex gets regulated through three main ways: covalent modification (the main regulatory method), allosteric regulation, and transcriptional regulation [6]. These processes will give a proper acetyl-CoA production based on the cell's energy needs.
NADH Generation from Isocitrate and α-Ketoglutarate
The TCA cycle produces more NADH at several key steps once acetyl-CoA enters it. The change of isocitrate to α-ketoglutarate is the rate-limiting step of the cycle. Isocitrate dehydrogenase (IDH) catalyzes this reaction and performs oxidative decarboxylation of isocitrate while reducing NAD+ to NADH [7].
IDH comes in multiple forms with different functions:
-
IDH3 catalyzes the third step of the TCA cycle while converting NAD+ to NADH in the mitochondria
-
IDH1 and IDH2 catalyze similar reactions outside the TCA cycle context, utilizing NADP+ instead of NAD+ [7]
The IDH-catalyzed reaction happens in two steps: isocitrate first oxidizes to oxalosuccinate (a ketone intermediate), which then undergoes decarboxylation to form α-ketoglutarate [7]. Each isocitrate molecule processed creates one NADH molecule, one CO2 molecule, and one proton. The reaction's overall free energy change is -8.4 kJ/mol [7].
The α-ketoglutarate dehydrogenase complex (KGDH) catalyzes α-ketoglutarate's conversion to succinyl-CoA. This complex works like PDC and needs thiamine pyrophosphate, lipoic acid, coenzyme A, NAD+, and FAD as cofactors [6]. The reaction creates another NADH molecule, along with CO2 and H+ [6].
IDH and KGDH both respond to allosteric regulation. ADP and calcium ions increase IDH activity, while ATP and NADH slow it down [6]. This regulation helps the TCA cycle respond to the cell's energy needs.
Ten NADH molecules are generated [8] from each glucose molecule that goes through glycolysis and the TCA cycle. Each NADH molecule that enters the electron transport chain at Complex I can make about 2.5 ATP molecules through oxidative phosphorylation [6]. NADH production in glycolysis and the TCA cycle are the foundations of how cells get chemical energy from nutrients.
NADH Dehydrogenase Function in the Electron Transport Chain
The electron transport chain (ETC) has NADH dehydrogenase at its core. This molecular giant, known as Complex I, acts as the main electron acceptor from NADH oxidation and starts a chain of redox reactions that power ATP synthesis.
Complex I as NADH Oxidation Site
Complex I stands out as a sophisticated enzymatic structure and the biggest component of the respiratory chain. This L-shaped protein complex extends across the inner mitochondrial membrane with impressive dimensions. Mammalian Complex I has approximately 46 subunits and weighs close to 1,000 kilodaltons [9]. The enzyme has two distinct domains: a hydrophilic peripheral arm that extends into the mitochondrial matrix and a hydrophobic membrane domain embedded in the inner mitochondrial membrane [10].
NADH binds to Complex I at a site with flavin mononucleotide (FMN) to start the oxidation process. NADH gives two electrons to FMN, which turns it into FMNH₂ [1]. This electron transfer follows the reaction:
NADH + H⁺ + CoQ + 4H⁺(matrix) → NAD⁺ + CoQH₂ + 4H⁺(intermembrane) [1]
Electrons move from FMN through an amazing electron pathway made up of eight iron-sulfur (Fe-S) clusters positioned strategically in the complex [1]. These clusters create an electron transfer chain that delivers electrons to ubiquinone (Coenzyme Q or CoQ). The redox reactions and proton pumping machinery work together through protein structure changes, despite being physically apart [11].
Complex I's architecture helps its function. The peripheral arm contains the NADH binding site, FMN, and iron-sulfur clusters. The membrane domain has three subunits with discontinuous helices that form proton pumping sites [12]. The membrane arm's subunits L, M, and N share similarities with bacterial proton/cation antiporters [10].
Proton Pumping and ATP Synthesis
Complex I moves four protons from the mitochondrial matrix to the intermembrane space when it oxidizes each NADH molecule [1]. This creates an electrochemical gradient across the inner mitochondrial membrane, also called the proton-motive force [3].
The gradient stores potential energy that drives ATP synthesis. Electron transfer releases energy through the complex and triggers changes that allow proton movement [12]. The ubiquinone reduction gives energy for proton pumping through an "electrostatic pulse" carried by chains of acidic and basic amino acids [12].
ATP synthase (Complex V) uses the proton gradient from NADH oxidation. This molecular rotary motor has F₀ and F₁ subunits [1]. Protons flowing back to the matrix through the F₀ channel rotate the F₁ component, which makes ATP from ADP and inorganic phosphate [13]. Each ATP molecule forms when four protons return to the matrix [1].
One NADH molecule oxidized at Complex I adds a lot to cellular ATP production. A complete NADH oxidation moves ten protons through the ETC (four from Complex I, four from Complex III, and two from Complex IV) [1]. ATP synthase needs about four protons to make one ATP molecule, so each NADH can produce about 2.5 ATP molecules [1].
Complex I affects many physiological processes beyond energy production. The complex can create reactive oxygen species (ROS), especially during reverse electron transport [14]. These ROS can damage cells in disease states but also work as important signal molecules in immune responses and cell regulation [14].
Complex I dysfunction links to many diseases, including neurodegenerative conditions and mitochondrial disorders [15]. Understanding NADH dehydrogenase's detailed mechanisms gives us crucial insights into normal cell function and disease development.
Redox Balance and NAD/NADH Function in Cells
The NAD+/NADH redox couple acts as a key regulatory system in cells that goes way beyond the reach and influence of energy production. A well-balanced redox system significantly affects cellular health and serves as both an indicator and controller of metabolic status.
Maintaining NAD+/NADH Ratio
Different cellular compartments need different NAD+/NADH ratios to handle their specialized functions. Research shows that cytoplasmic NAD+/NADH ratios range between 60 and 700 in typical eukaryotic cells. The mitochondrial NAD+/NADH ratios stay much lower at about 7 to 8 [16]. This separation lets the cell carry out different metabolic activities at the same time.
Each cell type has its own mitochondrial NAD pool:
-
Cardiac myocytes hold 70% of total cellular NAD (10.0±1.8 nmol/mg protein)
-
Neurons contain 50% (4.7±0.4 nmol/mg protein)
-
Hepatocytes and astrocytes have 30-40% (3.2±1.0 nmol/mg protein) [16]
The mitochondrial NAD pool shows amazing resilience. Even when cytoplasmic NAD drops drastically, mitochondrial levels stay stable for up to 3 days [16]. This strong separation helps maintain oxidative phosphorylation during temporary metabolic disruptions.
Several enzymes help regulate NAD+/NADH balance. NAMPT (nicotinamide phosphoribosyltransferase) guides the NAD+ salvage pathway and maintains cellular NAD+ levels [17]. CD38 and sirtuins use up NAD+, and their activity directly affects the overall ratio [17]. These opposing processes create a dynamic balance that adapts to what cells need.
Redox Stress and Metabolic Regulation
Redox stress includes both oxidative and reductive imbalances. We see oxidative stress when pro-oxidants exceed antioxidant capacity. Reductive stress happens when too many reducing equivalents build up [18]. Both conditions disrupt normal cell functions through different mechanisms.
NADH buildup leads to reductive stress, which creates oxidative damage [19]. This unexpected relationship comes from NADH's role in creating reactive oxygen species (ROS). Extra NADH can send electrons to NOX enzymes (NADPH oxidases) or cause reverse electron transport in the ETC, which ended up producing superoxide and hydrogen peroxide [20].
NAD+/NADH ratio controls metabolism through multiple ways:
-
Enzymatic regulation - Many dehydrogenases respond to NAD+/NADH levels directly. High NADH stops TCA cycle enzymes like isocitrate dehydrogenase from working [21]
-
Sirtuin activity - NAD+-dependent sirtuins change gene expression by removing acetyl groups from histones, which affects metabolism-related genes [22]
-
Redox signaling - NAD+/NADH ratio affects cellular ROS levels and influences redox-sensitive signaling pathways [20]
-
RNA modification - NAD+ molecules help in RNA capping, which changes translation efficiency based on cellular redox status [22]
Problems with NAD+/NADH balance relate to many diseases. A constantly low NAD+/NADH ratio relates to diabetes [22]. NAD+ depletion affects neuronal plasticity, cellular aging, and DNA repair [22]. High glucose levels increase NADH production, which creates redox imbalance and insulin resistance [2].
Research shows promising results for NAD+ restoration therapies in animal models of cardiometabolic disease [4]. It also helps to adjust NADPH levels (closely connected to NADH through enzyme conversions). This affects antioxidant capacity through glutathione regeneration systems [20], offering another path for redox-based treatments.
NADH Transport Limitations and Shuttle Systems
The inner mitochondrial membrane blocks both NADH and NAD+ from passing through, which creates a major constraint in cellular bioenergetics. Cytosolic NADH can't enter mitochondria directly to be oxidized by the electron transport chain (ETC). Cells have evolved special shuttle systems that help transport reducing equivalents across the membrane boundary to solve this problem. These systems keep metabolic processes running smoothly between cytosolic and mitochondrial compartments [23].
These shuttles help maintain different levels of NADH and NAD+ between cellular compartments. This allows separate control of redox status in each area. The transport of NADH from cytosol to mitochondria happens through oxidative-reductive reactions instead of direct molecular movement [23].
Malate-Aspartate Shuttle in Neurons
Neurons and other high-energy tissues use the malate-aspartate shuttle (MAS). This shuttle moves electrons without using up metabolites, which makes it ideal for tissues that need constant energy production [24].
The process works through these steps:
-
A transaminase enzyme in the cytoplasm removes an amino group from aspartate to make oxaloacetate
-
Cytosolic malate dehydrogenase turns oxaloacetate into malate while changing NADH to NAD+
-
Malate crosses the inner mitochondrial membrane through a specific transporter
-
Malate changes back to oxaloacetate in the matrix, turning NAD+ into NADH
-
Oxaloacetate becomes aspartate and goes back to the cytosol to complete the cycle
MAS is a vital shuttle in neurons that links neuronal activity with energy production [25]. Scientists have found that calcium levels in the cytosol regulate MAS, which allows precise coordination between nerve firing and mitochondrial breathing [25]. MAS activity increases when calcium levels stay below the mitochondrial calcium uniporter threshold, but too much calcium might slow down the shuttle [25].
MAS activity affects insulin release in pancreatic beta cells. When researchers increased Aralar1 (a calcium-sensitive MAS component) using adenovirus, glucose-triggered mitochondrial activation and insulin secretion went up by 33%, while lactate release decreased [8].
G3P Shuttle in Muscle and Liver
Muscle and liver cells mainly use the glycerol-3-phosphate shuttle (G3P shuttle) to oxidize NADH [26]. This shuttle works more simply than MAS:
-
Cytosolic glycerol-3-phosphate dehydrogenase turns dihydroxyacetone phosphate (DHAP) into glycerol-3-phosphate (G3P), changing NADH to NAD+
-
G3P moves to the intermembrane space
-
Mitochondrial G3P dehydrogenase changes G3P back to DHAP, turning FAD into FADH₂
-
Electrons from FADH₂ enter the ETC at Complex III through ubiquinone [27]
|
Characteristic |
Malate-Aspartate Shuttle |
G3P Shuttle |
|---|---|---|
|
Tissues |
Neurons, heart, liver |
Muscle, liver, brown fat |
|
Energy yield |
2.5 ATP per NADH |
|
|
Regulation |
Ca²⁺-sensitive |
Energy status dependent |
|
Complexity |
Higher (multiple enzymes) |
Lower (two enzymes) |
The G3P shuttle produces less energy because it skips Complex I, making only 1.5 ATP molecules per NADH [27]. All the same, this lower efficiency serves a purpose in brown fat tissue by generating heat. This heat production helps babies and maintains small amounts of brown fat around adults' kidneys and necks [24].
New research shows that the G3P shuttle component mGPDH does more than just help with energy metabolism. It controls lipogenic genes like PPARγ, SREBP-1c, and FASN in liver cells, connecting NADH shuttling to broader metabolic pathways [28].
Yeast studies show that increasing shuttle components extends lifespan by about 25%, similar to eating less [29]. When shuttle systems don't work properly, the life-extending effects of calorie restriction stop working. This shows these shuttles matter for metabolic health beyond just providing energy [29].
These shuttle systems work in different tissues to keep glycolysis going by making more cytosolic NAD+ and giving mitochondria reducing equivalents. This supports NADH's role in cellular breathing across cells of all types.
NADH Accumulation Under Hypoxia and Its Consequences
Image Source: ResearchGate
Cells experience severe metabolic disruptions when they don't get enough oxygen. This happens mainly through accumulation of NADH. The electron transport chain fails to convert NADH to NAD+ efficiently at low oxygen levels. This creates a metabolic bottleneck that leads to widespread effects.
ETC Inhibition and Feedback on TCA
Cells see a dramatic spike in NADH levels as oxygen becomes too scarce to accept electrons [30]. Research on heart tissue shows that working hearts react strongly to even small drops in oxygen. Their NADH levels rise quickly [30]. Heart tissue reaches half-maximal NADH accumulation once oxygen drops below 68%. This shows how quickly low oxygen levels affect the tissue [30].
Cells switch on the hypoxia-inducible factor 1 (HIF-1) signaling pathway as oxygen stays low. This helps them reshape their metabolism. HIF-1 boosts pyruvate dehydrogenase kinase 1 (PDK1) production. PDK1 then deactivates the pyruvate dehydrogenase complex through phosphorylation [5]. This calculated shutdown stops pyruvate from becoming acetyl-CoA and reduces carbon flow into the TCA cycle [31]. On top of that, HIF-1 triggers siah E3 ubiquitin ligase 2 (SIAH2). SIAH2 breaks down oxoglutarate dehydrogenase (OGDH), which further limits TCA cycle activity [5].
Lactate Buildup and Redox Imbalance
Cells need to keep glycolysis running even with broken oxidative phosphorylation. They achieve this by turning pyruvate into lactate instead. HIF-1 increases lactate dehydrogenase A (LDH-A) production. LDH-A converts pyruvate to lactate and helps make more NAD+ [5]. HIF-1 also produces more monocarboxylate transporter 4 (MCT4). This helps pump out excess lactate and keeps the cell's pH balanced [5].
Rising lactate levels create more metabolic problems, though this helps at first. High lactate raises the NADH/NAD+ ratio. This blocks both glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and phosphoglycerate dehydrogenase (PGDH) [32]. The cell ends up damaging glycolysis - the very process it needs to survive with low oxygen.
Too much NADH leads to both reductive and oxidative stress. NADH reduces other molecules, but having too much can boost reactive oxygen species production. This happens through reverse electron transport at Complex I [19]. These effects explain why excess NADH damages mitochondria, disrupts membrane permeability, and harms proteins, DNA, and lipids through oxidation [19].
NADH in One-Carbon Metabolism and Cancer
One-carbon metabolism plays a crucial role in cancer metabolic rewiring. Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) regulates NADH production in tumor cells. This metabolic pathway supports nucleotide synthesis and maintains redox balance in challenging tumor environments.
MTHFD2-Mediated NADH Production
MTHFD2 works as a bifunctional enzyme in mitochondrial one-carbon metabolism. It catalyzes two sequential reactions. The first converts 5,10-methylene-THF to 5,10-methenyl-THF through dehydrogenase reaction. The second transforms 5,10-methenyl-THF to 10-formyl-THF via cyclohydrolase reaction. MTHFD2's expression occurs mainly in embryonic and transformed cells, unlike its cytosolic counterpart MTHFD1 that expresses everywhere as a housekeeping gene.
MTHFD2 acts as an NAD+/NADP+-dependent enzyme that regulates cellular redox state. Researchers used isotopic tracing experiments with 2H-serine to identify MTHFD2-dependent labeling of NADH in various mouse tissues and tumor models. Serine-derived NADH production matches levels of known TCA cycle substrates like 2H-glutamine, 2H-lactate, and 2H-palmitate, which shows its physiological importance.
Lab tests show purified MTHFD2 has no feedback inhibition by NADH. This makes it different from other NADH-generating processes. The folate metabolism through this pathway contributes up to 40% of NADPH production in immortalized mouse kidney epithelial cells [33].
Implications for Tumor Growth and Hypoxia
MTHFD2 stands out as the most upregulated metabolic gene between cancer cells and matched normal tissue [7]. SHMT2 ranks fifth among upregulated metabolic genes in cancer [7]. This upregulation helps tumor growth in several ways.
MTHFD2 maintains redox homeostasis in cancer cells and promotes tumor growth and metastasis. Cancer cells become more vulnerable to oxidative stressors, especially during hypoxia, when MTHFD2 is suppressed [33]. The suppression reduces NADPH/NADP+ and GSH/GSSG ratios, increases reactive oxygen species, and leads to more cell toxicity under oxidative stress.
Cancer cells need MTHFD2 to survive during hypoxia. Reduced MTHFD2 leads to poor hypoxic induction of the GSH/GSSG ratio, higher ROS levels, and more cell death. HIF-1α increases MTHFD2 and SHMT2 during hypoxic conditions [7]. Cancer cells depend on this metabolic pathway to survive.
MTHFD2 also helps maintain the genome during rapid cell division. It sits next to newly replicated DNA and helps with DNA damage repair.
Therapeutic Targeting of NADH Pathways
Recent studies about NADH metabolism have shown promising therapeutic strategies that target redox imbalances in diseases of all types, especially cancer and metabolic disorders.
Inhibiting NADH Overproduction in Hypoxic Tumors
Chronic hypoxia leads to excessive NADH accumulation which triggers HIF-1α degradation through SIRT1 inhibition [34]. This mechanism offers a new target for cancer therapy because NADH acts as a signal for HIF-1α decay through the SIRT1 and VHL signaling pathway. High NADH levels make HIF-1α acetylation possible by p300, which promotes its degradation [34].
Complex I inhibition stands out as another strategic approach. DX2-201, a first-in-class NDUFS7 antagonist, suppresses pancreatic cancer cell proliferation effectively [35]. The combination of Complex I inhibitors with glycolytic inhibitors like 2-deoxyglucose (2-DG) helps overcome drug resistance in vivo [35]. As with other compounds, capsaicin causes apoptosis in pancreatic cancer cells by blocking Complex I and III enzymes, which raises ROS production [36].
MTHFD2 inhibitors target one-carbon metabolism to lower cellular NADPH/NADP+ ratio, boost ROS levels, and slow down tumorigenesis [37].
Potential of NAD+ Precursors in Redox Therapy
NAD+ precursor supplementation offers another promising therapeutic path. The four main NAD+ precursors—nicotinic acid (NA), niacinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN)—help treat metabolic dysfunction differently [6].
NR stands out among these options with better results in increasing NAD+ content and NAD+/NADH ratio [6]. NR's antioxidative properties in hepatocytes work through Sirt3-mediated antioxidant enzyme activation [6]. On top of that, it shows strong anti-inflammatory and anti-apoptotic effects by increasing PARPs activity, which enhances DNA repair [6].
NAD+ precursors show promise beyond cancer treatment. NAD+ repletion in preclinical models extends healthspan and reduces several conditions, including premature aging diseases and neurodegenerative disorders [38]. Scientists now study NAD+ precursors to treat Alzheimer's disease and other age-related conditions [38].
Conclusion
NADH is the life-blood molecule in cellular bioenergetics that orchestrates many metabolic processes vital for life. Our research shows NADH's diverse functions are key factors in cellular health and energy production. NADH mainly works as an electron carrier in redox reactions that connects glycolysis to oxidative phosphorylation and regulates metabolic flux through its effects on enzymatic pathways.
Complex I, a massive protein assembly, sits at the start of the electron transport chain and serves as the main site for NADH oxidation. It generates about 2.5 ATP molecules per NADH molecule. This remarkable energy yield shows why aerobic respiration has such advantages over other metabolic strategies. The malate-aspartate and glycerol-3-phosphate shuttles are sophisticated systems that work around the mitochondrial membranes' impermeability to NADH. These shuttles ensure metabolic continuity between cellular compartments.
Redox balance plays a significant role in NADH function. Cells keep distinct NAD+/NADH ratios across compartments, which allows specialized metabolic activities throughout the cell to happen simultaneously. When this balance gets disrupted, especially during hypoxia, NADH accumulates and creates major changes in cellular metabolism. Cancer cells take advantage of these pathways, particularly through MTHFD2-mediated NADH production in one-carbon metabolism, which helps tumors grow in challenging environments.
Recent therapeutic strategies that target NADH pathways look promising. Complex I inhibitors successfully suppress cancer cell growth, while NAD+ precursors show potential in treating metabolic disorders and age-related conditions. Nicotinamide riboside stands out with its superior effects in boosting NAD+ content and improving the NAD+/NADH ratio. It offers antioxidative properties through Sirt3-mediated enzyme activation.
Scientists will find more roles for NADH beyond what we know today. The complex relationships between NADH metabolism, redox signaling, and disease development offer rich opportunities for scientific exploration. A detailed understanding of NADH function gives us insights into basic cellular operations and creates valuable opportunities to treat various pathological conditions.
FAQs
Q1. What is the primary function of NADH in cellular energy production? NADH serves as a crucial electron carrier in cellular respiration. It donates electrons to the electron transport chain in mitochondria, driving the production of ATP, which is the primary energy currency of cells.
Q2. How does NADH contribute to ATP synthesis? NADH provides electrons for aerobic ATP production through the electron transport chain. Each NADH molecule oxidized can theoretically yield about 2.5 ATP molecules through oxidative phosphorylation.
Q3. What happens when NADH accumulates in cells? Excessive NADH accumulation, particularly during hypoxia, can lead to reductive stress and paradoxically increase reactive oxygen species production. This can inhibit key metabolic pathways and potentially damage cellular components.
Q4. How do cells maintain the balance between NAD+ and NADH? Cells maintain different NAD+/NADH ratios in various compartments through specialized shuttle systems like the malate-aspartate shuttle. Enzymes like NAMPT also help regulate this balance by participating in NAD+ salvage pathways.
Q5. What are some potential therapeutic applications targeting NADH pathways? Therapeutic strategies involving NADH pathways include using Complex I inhibitors to suppress cancer cell proliferation and administering NAD+ precursors like nicotinamide riboside to treat metabolic dysfunction and age-related disorders.
References
[1] - https://www.ncbi.nlm.nih.gov/books/NBK526105/
[2] - https://pmc.ncbi.nlm.nih.gov/articles/PMC7973386/
[3] - https://www.khanacademy.org/science/ap-biology/cellular-energetics/cellular-respiration-ap/a/oxidative-phosphorylation-etc
[4] - https://www.sciencedirect.com/science/article/abs/pii/S002228282400124X
[5] - https://pmc.ncbi.nlm.nih.gov/articles/PMC6453877/
[6] - https://www.mdpi.com/2076-3921/13/4/385
[7] - https://www.sciencedirect.com/science/article/pii/S1550413120301273
[8] - https://www.sciencedirect.com/science/article/pii/S0021925818663331
[9] - https://en.wikipedia.org/wiki/Oxidative_phosphorylation
[10] - https://www.pnas.org/doi/10.1073/pnas.1120949109
[11] - https://www.sciencedirect.com/science/article/pii/S0005272816300329
[12] - https://www.sciencedirect.com/science/article/pii/S0925443920301460
[13] - https://www.ncbi.nlm.nih.gov/books/NBK9885/
[14] - https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.202101161R
[15] - https://link.springer.com/10.1007%2F978-3-642-16712-6_26
[16] - https://pmc.ncbi.nlm.nih.gov/articles/PMC3683958/
[17] - https://www.nature.com/articles/s42003-020-01514-y
[18] - https://pmc.ncbi.nlm.nih.gov/articles/PMC7247050/
[19] - https://pmc.ncbi.nlm.nih.gov/articles/PMC4869616/
[20] - https://pmc.ncbi.nlm.nih.gov/articles/PMC5737637/
[21] - https://www.nature.com/articles/s41392-020-00354-w
[22] - https://www.promegaconnections.com/decoding-the-nad-nadh-ratio-and-its-crucial-role-in-cell-health/
[23] - https://pmc.ncbi.nlm.nih.gov/articles/PMC2636997/
[24] - https://en.wikipedia.org/wiki/Mitochondrial_shuttle
[25] - https://link.springer.com/article/10.1007/s11064-015-1652-8
[26] - https://ontosight.ai/glossary/term/glycerol-3-phosphate-shuttle-pathway-mechanism--67a136966c3593987a5489ae
[27] - https://aklectures.com/lecture/glycerol-3-phosphate-shuttle
[28] - https://pmc.ncbi.nlm.nih.gov/articles/PMC6597300/
[29] - https://pmc.ncbi.nlm.nih.gov/articles/PMC2279204/
[30] - https://pmc.ncbi.nlm.nih.gov/articles/PMC3920244/
[31] - https://pmc.ncbi.nlm.nih.gov/articles/PMC3063979/
[32] - https://www.nature.com/articles/s41392-022-01151-3
[33] - https://pmc.ncbi.nlm.nih.gov/articles/PMC7199629/
[34] - https://pmc.ncbi.nlm.nih.gov/articles/PMC10543270/
[35] - https://pubs.acs.org/doi/10.1021/acsptsci.3c00069
[36] - https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1243613/pdf
[37] - https://www.nature.com/articles/s41392-020-00326-0
[38] - https://www.sciencedirect.com/science/article/pii/S0047637421001391
